2,6-dihydroxy-3-cyanopyridine has been researched along with Sarcoma 180 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujii, S; Fukushima, M; Imaoka, T; Ohshimo, H; Shimamoto, Y; Shirasaka, T | 1 |
Fujii, S | 1 |
2 other study(ies) available for 2,6-dihydroxy-3-cyanopyridine and Sarcoma 180
Article | Year |
---|---|
Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Fluorouracil; Mice; Mice, Inbred ICR; Pyridines; Rats; Sarcoma 180; Sarcoma, Yoshida | 1989 |
[BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Floxuridine; Fluorouracil; Liver; Mice; Pyridines; Pyrimidines; Rats; Sarcoma 180; Sarcoma, Experimental; Sarcoma, Yoshida; Tegafur; Uracil | 1987 |